Alectinib

Therapeutic indications

Alectinib is indicated for:

Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Population group: both men and women, only adults (18 years old or older)

Alectinib as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Alectinib as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines